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HIV/AIDS pandemics is a serious threat to health and development of mankind, and searching for eﬀective anti-HIV agents
remains actual. Considerable progress has been made in recent years in the ﬁeld of drug development against HIV. A lot of struc-
turally diﬀerent coumarins were found to display potent anti-HIV activity. The current review demonstrates the variety of syn-
thetic coumarins having unique mechanism of action referring to the diﬀerent stages of HIV replication. Recent studies based
on the account of various synthetic coumarins seem to indicate that some of them serve as potent non-nucleoside RT-inhibitors,
another as inhibitors of HIV-integrase or HIV-protease. The merits of selecting potential anti-HIV agents to be used in rational
combination drugs design and structure-activity relationships are discussed.The scientiﬁc community is looking actively for new
drugs and combinations for treatment of HIV infection eﬀective for ﬁrst-line treatment, as well as against resistant mutants. The
investigation on chemical anti-HIV agents gives hope and optimism about it. This review article describes recent progress in the
discovery, structure modiﬁcation, and structure-activity relationship studies of potent anti-HIV coumarin derivatives.
Copyright © 2006 I. Kostova et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
AIDS remains an enormous health threat, although chemo-
therapeutic agents have increased in number and eﬀective-
ness.Bothnucleoside(AZT,DDI,DDC,D4T,3TC)andnon-
nucleoside (nevirapine, delavirdine) HIV reverse transcrip-
tase (RT) inhibitors and HIV protease (saquinavir, indinavir,
ritonavir, nelﬁnavir) inhibitors have been licensed by the US
FDA. Also, combination therapy of inhibitors of both groups
results in undetectable levels of HIV in the blood of infected
patients. However, despite this success, toxicity and, espe-
cially, drug resistance still present severe problems.
ThereplicativecycleofHIViscomprisedoftenstepsthat
may be adequate targets for chemotherapeutical interven-
tion. Most of the substances identiﬁed as anti-HIV agents in-
terfere with one of these steps of HIV replicative cycle. These
steps are: (1) viral adsorption to the cell membrane, (2) fu-
sion between the viral envelope and the cell membrane, (3)
uncoating of the viral nucleocapsid, (4) reverse transcrip-
tion of the viral RNA to proviral DNA, (5) integration of the
proviral DNA into the cellular genome, (6) DNA replication,
(7)transcriptionoftheproviralDNAtoRNA,(8)translation
of the viral precursor mRNA to mature mRNA, (9) matura-
tion of the viral precursor proteins by proteolysis, myristoy-
lation, and glycosylation, and (10) budding, virion assembly,
and release. Step 4, a key step in the replicative cycle of retro-
viruses, which makes it distinct from the replicative cycle of
other viruses, is the reverse transcription catalyzed by reverse
transcriptase. Another target for therapeutic intervention is
step 9, particularly the proteolysis of precursor proteins by
HIV protease. The majority of chemotherapeutic strategies
have, therefore, focused on the development of retroviral en-
zyme inhibitors.
The US Food and Drug Administration (FDA) has ap-
proved a number of anti-HIV drugs for clinical use. How-
ever, these medications have limitations such as high cost,
decreased sensitivity due to the rapid emergence of drug-
resistant mutants, and adverse eﬀects like peripheral neu-
ropathy, bone marrow suppression, and anemia [1]. Thus,
more eﬀective and less toxic anti-HIV agents are still needed.
In addition, alternative approaches, including herbal thera-
pies after long-term screening of plant extracts, particularly
anti-infective or immunomodulating medicinal herbs and
thestructuralmodiﬁcationofleadcompounds,havebeenat-
tempted.
Coumarins, an old class of compounds, are naturally oc-
curring benzopyrene derivatives. A lot of coumarins have
been identiﬁed from natural sources, especially green plants.
The pharmacological and biochemical properties and ther-
apeutic applications of simple coumarins depend upon the2 Bioinorganic Chemistry and Applications
pattern of substitution. Coumarins have attracted intense in-
terestinrecentyearsbecauseoftheirdiversepharmacological
properties.
Coumarins comprise a group of natural compounds
found in a variety of plant sources. The very long associ-
ation of plant coumarins with various animal species and
other organisms throughout evolution may account for the
extraordinary range of biochemical and pharmacological ac-
tivitiesofthesechemicalsinmammalianandotherbiological
systems. The coumarins that were studied have divers bio-
logical properties and various eﬀects on the diﬀerent cellu-
lar systems. A lot of biological parameters should be evalu-
ated to increase our understanding of mechanisms by which
these coumarins act. Coumarins have important eﬀects in
plant biochemistry and physiology, acting as antioxidants,
enzyme inhibitors, and precursors of toxic substances. In
addition, these compounds are involved in the actions of
plant growth hormones and growth regulators, the control
of respiration, photosynthesis, as well as defense against in-
fection. The coumarins have long been recognized to pos-
sess anti-inﬂammatory, antioxidant, antiallergic, hepatopro-
tective,antithrombotic,antiviral,andanticarcinogenicactiv-
ities.Thehydroxycoumarinsaretypicalphenoliccompounds
and, therefore, act as potent metal chelators and free radical
scavengers. They are powerful chain-breaking antioxidants.
The coumarins display a remarkable array of biochemical
andpharmacologicalactions,someofwhichsuggestthatcer-
tain members of this group of compounds may signiﬁcantly
aﬀect the function of various mammalian cellular systems.
The coumarins are extremely variable in structure, due
to the various types of substitutions in their basic struc-
ture, which can inﬂuence their biological activity. A careful
structure-system-activity-relationship study of coumarins
should be conducted.
Reversetranscriptaseinhibitors
Syntheticcalanolides
(+)-calanolide A (Scheme 1), (+)-[10R, 11S, 12S]-10,11-
trans-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-
2H,6H-benzo[1,2-b:3,4-b :5,6-b  ]tripyran-2-one, is a novel
non-nucleoside reverse transcriptase inhibitor (NNRTI)
withpotentactivityagainstHIV-1[2–4].Thecompoundwas
ﬁrst isolated from a tropical tree (Calophyllum lanigerum)
in Malaysia [4]. Due to low availability of naturally occur-
ring (+)-calanolide A, a total synthesis of this polycyclic
coumarin was developed to provide material for preclinical
and clinical research [4, 5]. Structural biology studies and
enzyme kinetic experiments bear out the unique anti-HIV
properties of calanolide A. In particular, calanolide A is
active against viral isolates with the Y181C amino acid
mutation in the reverse transcriptase of HIV-1. This is a
commonly observed mutation identiﬁed in both laboratory
and clinical viral isolates and is associated with high-level
resistance to most other NNRTIs. However, viral isolates that
contain multiple AZT-resistant mutations and the Y181C
mutation are actually hypersensitive to the antiviral activity
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Scheme 2: (−)-calanolide A.
of calanolide A. When tested in vitro in combination with
a range of nucleoside analogues, protease inhibitors and
NNRTIs, calanolide A demonstrates additive to synergistic
anti-HIV activity.
The anti-HIV agent (+/−)-calanolide A has been synthe-
sized [5–7] in a ﬁve-step approach starting with phlorogluci-
nol, which includes Pechmann reaction, Friedel-Crafts acy-
lation, chromenylation with 4,4-dimethoxy-2-methylbutan-
2-ol, cyclization, and Luche reduction. Cyclization of
chromene to chromanon was achieved by employing either
acetaldehyde diethyl acetal or paraldehyde in the presence
of triﬂuoroacetic acid and pyridine or PPTS. Luche reduc-
tion of chromanone at lower temperature preferably yielded
(+/−)-calanolide A. The synthetic (+/−)-calanolide A has
been chromatographically resolved into its optically active
forms, (+)- and (−)-calanolide A (Scheme 2). The anti-HIV
activities for synthetic (+/−)-calanolide A, as well as resul-
tant (+)- and (−)-calanolide A, have been determined. Only
(+)-calanolide A accounted for anti-HIV activity, which was
similar to the data reported forthe naturalproduct, and (−)-
calanolide A was inactive.I. Kostova et al 3
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Scheme 3: (−)-calanolide B.
In order to examine the structure-activity relationships
of the trans-10,11-dimethyldihydropyran-12-ol ring (desig-
nated ring C), a series of structural analogues were prepared
and evaluated using cell cytopathicity assay (XTT) [14]. Re-
moval of the 10-methyl group resulted in decreased activity,
with only one epimer exhibiting anti-HIV activity. Substi-
tuting the 10-methyl group with an ethyl chain maintained
anti-HIVactivity,withonlya4-foldreductioninpotencyrel-
ative to racemic calanolide A. Substitution of the 10-methyl
group with an isopropyl moiety completely eliminated the
anti-HIV activity. Addition of an extra methyl group at ei-
ther the 10- or 11-position maintained the basic stereochem-
ical features of the parent calanolide system while remov-
ing the chirality at the respective carbon, but resulted in
decreased activity relative to calanolide A. In the above ex-
amples, analogues containing a cis relationship between the
10- and 11-alkyl moieties were completely devoid of activ-
ity. Synthetic intermediates in which the 12-hydroxyl group
was in the ketone oxidation state exhibited suppressing anti-
HIV activity, with EC50 values only 5-fold less potent than
that of calanolide A for both the 10,11-cis and -trans series.
These ketones represent the ﬁrst derivatives in the calanolide
series to exhibit anti-HIV activity while not containing a 12-
hydroxyl group. Analogues which showed anti-HIV activity
in the CEM-SS cytoprotection assay were further conﬁrmed
to be inhibitors of HIV-1 reverse transcriptase. The synthesis
of calanolide A has been reported in [15–17].
The delta 7,8 oleﬁnic linkages within (+)-calanolide A
and (−)-calanolide B (Scheme 3) were catalytically reduced
to determine impact on the anti-HIV activity of the parent
compounds [18]. In addition, a series of structure modiﬁ-
cations of the C-12 hydroxyl group in (−)-calanolide B was
made to investigate the importance of that substituent to the
HIV-1 inhibitory activity of these coumarins. A total of 14
analogues were isolated or prepared and compared to (+)-
calanolide A and(−)-calanolide B in the National Cancer In-
stitute. While none of the compounds showed activity supe-
riortotheunmodiﬁedleads,somestructure-activityrequire-
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Scheme 4: (+)-12-oxocalanolide.
ments were apparent from the relative anti-HIV potencies of
the various analogues [19–22]. The synthesis of the isomers
of calanolide A has been reported in [23, 24].
NMR spectra of synthetic structures corresponding to
those initially reported for natural compounds calanolide C
and calanolide D showed some subtle diﬀerences from those
of the natural products. Further analysis has resulted in re-
vision of the structures of the natural compounds, now re-
named as pseudocalanolides C and D. The absolute stereo-
chemistry of pseudocalanolide C was established as [6S, 7S,
8R] using the modiﬁed Mosher’s method [25].
Thethreechromanonederivatives(+)-,(−)-,and(+/−)-
12-oxocalanolide A (Scheme 4)w e r ee v a l u a t e df o ri nv i t r o
antiviral activities against HIV and simian immunodeﬁ-
ciency virus (SIV). The compounds were determined to be
inhibitors of HIV-1 reverse transcriptase (RT) and exhibited
activity against a variety of viruses selected for resistance to
other HIV-1 non-nucleoside RT inhibitors. They are the ﬁrst
reported calanolide analogues capable of inhibiting SIV [26].
SyntheticDCKanalogues
Numerous plant-derived compounds have been evaluated
for inhibitory eﬀects against HIV replication, and some
coumarins have been found to inhibit diﬀerent stages in the
HIV replication cycle. The review article [27] describes re-
cent progress in the discovery, structure modiﬁcation, and
structure-activity relationship studies of potent anti-HIV
coumarin derivatives. A dicamphanoyl-khellactone (DCK)
analogue, which was discovered and developed in author’s
laboratory,andcalanolideAarecurrentlyinpreclinical stud-
ies and clinical trials, respectively.
Through a bioactivity-directed search for plant-derived,
naturally occurring compounds, the lead compound suku-
dorﬁn was isolated from the fruit of Lomatium suksdor-
ﬁi and its structure was identiﬁed. Sukudorﬁn (Scheme 5)
inhibited HIV-1 replication in H9 lymphocytes (the EC50
and the therapeutic index—TIs for some coumarins are4 Bioinorganic Chemistry and Applications
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Scheme 5: Suksdorﬁn.
reviewed in Table 1). The discovery of suksdorﬁn led to the
synthetic compounds and the most promising lead com-
pound was 3,4-di-O-(s)-(−)-camphanoyl-(3 R, 4 R)-(+)-
cis-khellactone(orDCK)Scheme 6,whichshowedextremely
potent activity [1].
Forty two dihydroseselins based on the structure of suks-
dorﬁn were synthesized in order to evaluate their anti-
HIV activity [8]. These synthetic derivatives include 3 ,4 -di-
O-acyl- and 3 -o r4  -O-acyl-cis-dihydroseselins and 3 ,4 -
trans-dihydroseselins with O-acyl and/or O-alkyl groups
at the 3  and 4  positions. Two 4 -azido and three 4 -
alkylamido derivatives were also prepared. By using opti-
cally pure reagents, three pairs of diastereoisomers were syn-
thesized and separated as optically pure compounds. To-
gether with the above synthetic derivatives, seselin Scheme 7
and (+/−)-cis-, (+)-cis-, and (+/−)-trans-dihydroseselin-
3 ,4 -diol were also tested for anti-HIV activity in vitro.
An optically pure compound, 3 ,4 -di-O-(−)-camphanoyl-
(+)-cis-khellactone, showed potent inhibitory activity and
remarkable selectivity against HIV replication. The EC50
value and in vitro therapeutic index (TI) of 3 ,4 -di-O-
(−)-camphanoyl-(+)-cis-khellactone are better than those
shown by AZT (Table 1). In addition, compound 3 ,4 -di-
O-(−)-camphanoyl-(+)-cis-khellactone is also active against
HIV replication in a monocytic cell line and in periph-
eral blood mononuclear cells (PBMCs). In vitro assay indi-
cated that, like compound suksdorﬁn, compound 3 ,4 -di-
O-(−)-camphanoyl-(+)-cis-khellactoneisnotaninhibitorof
HIV-1 reverse transcriptase. Moreover, the anti-HIV activity
of 3 ,4 -di-O-(−)-camphanoyl-(+)-cis-khellactone is stere-
oselective as its three diastereoisomers are at least 10,000
times less active. Since other synthetic dihydroseselin deriva-
tives with diﬀerent substituents or without any substituents
are inactive or are active only at much higher concentra-
tion, the antiviral potency of 3 ,4 -di-O-(−)-camphanoyl-
(+)-cis-khellactone could be associated with the camphanoyl
moieties of its structure. Therefore, compound 3 ,4 -di-
O-(−)-camphanoyl-(+)-cis-khellactone represents a unique
coumarin structure with promising anti-HIV activity.
DCK lactam analogues were synthesized [9]a n de v a l u -
atedinH9cells.4-methyl-DCKlactamexhibitedpotentanti-
HIV activity (Table 1).
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Scheme 7: Seselin.
A series of disubstituted 3 ,4 -di-O-(S)-camphanoyl-
(+)-cis-khellactone (DCK) analogues were synthesized [10]
and evaluated for inhibition of HIV-1 replication in H9 lym-
phocytes.5-methoxy-4-methylDCKwasthemostpromising
compound.AsseeninTable 1,itsparametersweremuchbet-
ter than those of lead compound DCK. Another six disubsti-
tutedDCKanaloguesweremorepotentthanAZTbutlessac-
tive than DCK. Conformational analysis suggested that res-
onance of the coumarin system is an essential structural fea-
ture for potent anti-HIV activity. Steric compression of C(4)
and C(5) substituents of the coumarin moiety can reduce
the overall planarity and thus resonance of the coumarin nu-
cleus, resulting in a decrease or lack of anti-HIV activity.
To explore the structural requirements of (+)-cis-
khellactone derivatives as novel anti-HIV agents, 24 mono-
substituted 3 ,4 -di-O-(S)-camphanoyl-(+)-cis-khellactone
(DCK) derivatives were synthesized in enantiometrically
pure form [12]. These compounds included four isomeric
monomethoxy analogues, four isomeric monomethyl ana-
logues, four 4-alkyl/aryl-substituted analogues, and twelve
4-methyl-(+)-cis-khellactone derivatives with varying 3 ,4 -
substituents. These (+)-cis-khellactone derivatives were
screened in acutely infected H9 lymphocytes. The results
demonstrated that the (3 R, 4 R)-(+)-cis-khellactone skele-
ton, two (S)-(−)-camphanoyl groups at the 3 -a n d4  -
positions, and a methyl group on the coumarin ring, except
at the 6-position, were optimal structural moieties for anti-
HIV activity. EC50 and TI values for 3-methyl-, 4-methyl-,I. Kostova et al 5
Table 1: A review of EC50 values and TIs (deﬁned as LD50/IC50) for some coumarins.
Compound EC50 TI Reference
Suksdorﬁn 1,3μM > 40 [1]
3 ,4 -di-O-(−)-camphanoyl- 4 ×10−4 μM∗ 136,719
(+)-cis-khellactone
[8]
4-methyl-DCK lactam 0,00024μM 119,333 [9]
5-methoxy-4-methyl DCK 7,21 ×10−6 μM > 2,08 ×107 [10]
3-hydroxymethyl-4-methyl-DCK 0,004μMi nH 9c e l l s —
0,024μMi nP B M C ∗∗ [11]
3-methyl-, 4-methyl-, and 5-methyl-
5,25×10−5 μM2 , 1 5 ×106 3 ,4 -di-O-(S)-camphanoyl-
(3 R, 4 R)-(+)-cis-khellactone
[12]
3-hydroxymethyl DCK 1,87 ×10−4 μM1 , 8 9 ×105 [13]
4-methyl-3 ,4 -di-O-(−)- 0,00718μM > 21000
camphanoyl-(+)-cis-khelthiolactone
[1]
3-bromomethyl-4-methyl-DCK 0,00011μM 189 600 [11]
∗here IC50 but not EC50 is reported
∗∗peripheral blood mononuclear cells
and 5-methyl-3 ,4 -di-O-(S)-camphanoyl-(3 R, 4 R)-(+)-
cis-khellactoneareshowninTable 1.Furthermore,4-methyl-
, and 5-methyl-3 ,4 -di-O-(S)-camphanoyl-(3 R, 4 R)-(+)-
cis-khellactone also showed potent inhibitory activity in
CEM-SScellline,andmostmonosubstitutedDCKanalogues
were less toxic than DCK.
Six 3-substituted 3 ,4 -di-O-(S)-camphanoyl-(+)-cis-
khellactone derivatives were synthesized from 3-methyl
DCK. 3-hydroxymethyl DCK exhibited potent anti-HIV
activity in H9 lymphocytes shown in Table 1. These values
are similar to those of DCK and better than those of AZT
[13].
In additional structure-activity-relationship (SAR) stud-
ies [1], the carbonyl oxygen of DCK was replaced with a sul-
fur atom. This bioisostere was less potent but also less cy-
totoxic than DCK. The 4-methyl, -propyl, and -benzyl ana-
logues were also prepared; the order of activity was methyl >
H > propyl > benzyl. 4-methyl-3 ,4 -di-O-(−)-camphonyl-
(+)-cis-khelthiolactone exhibited extremely potent anti-HIV
activity (Table 1).
To enhance the water solubility and oral bioavailability
of DCK analogues, 12 new mono- and disubstituted (3 R,
4 R)-3 ,4 -di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK)
analogues were synthesized and evaluated for inhibi-
tion of HIV-1 replication in H9 lymphocytes [11]. 3-
hydroxymethyl-4-methyl-DCK exhibited signiﬁcant anti-
H I Va c t i v i t yi nH 9l y m p h o c y t e sa n de v e nl e s si np r i -
mary peripheral blood mononuclear cells (Table 1). Al-
though this compound was not as potent as 4-methyl-DCK
and 3-bromomethyl-4-methyl-DCK, it provides increased
water solubility and possible linkage to other moieties.
Ofparticularnote,3-hydroxymethyl-4-methyl-DCKexhibits
moderate oral bioavailability (15%) when administered as
a carboxymethylcellulose suspension to rats, whereas 4-
methyl-DCK is not orally bioavailable in the same formu-
lation. Further studies on mechanism of action suggest that
3-hydroxymethyl-4-methyl-DCK inhibits the production of
double-stranded viral DNA from the single-stranded DNA
intermediate. In addition, 3-bromomethyl-4-methyl-DCK is
the most potent compound in this series of new analogues
with EC50 and TI values shown in Table 1. Thus, further
modiﬁcation at the 3-position of the coumarin ring can im-
prove the potency of new DCK analogues.
Otherreversetranscriptaseinhibitors
Ten diﬀerent pyranone-related substituents (chromones or
coumarins) were covalently linked to the 5  end of vari-
ous oligonucleotides (ODNs). The interaction of these com-
pounds with HIV-1 RT was analyzed. A diﬀerent behav-
ior was found to depend on the structure of the oligonu-
cleotide derivatives. Some compounds activated the en-
zyme at relatively low concentrations (0.1–0.5μM), fol-
lowed by inhibition of the activity at higher concentra-
tions (5–20μM), whereas others behave just as inhibitors.
Because the presence of some coumarin or chromone
derivatives conjugated to ODNs enhanced the interac-
tion with RT, Martyanov et al [28] analyzed the ca-
pacity of such ODN derivatives to be used as primers.
The introduction of a chromone derivative, the 2-[3-
(aminopropyl)amino]-8-isopropyl-5- methyl-4-oxo-4H-1-
benzopyran-3-carbaldehyde], and a coumarin derivative,
the 1-(3-aminopropoxy)-2-ethyl-3H-naphto [2,1-b] pyran-
3-one, into the 5  end of a noncomplementary ODN allowed6 Bioinorganic Chemistry and Applications
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these compounds to be used as primers. In the case of com-
plementary primers, the presence of conjugated derivatives
enhanced the aﬃnity with Km values that were two to three
orders of magnitude lower than that of a complementary
primer of the same length. After addition of a ddT-unit to
the 3 -terminal end of the ODN, some of these primers be-
came very eﬀective inhibitors of RT with Ki values in the
nanomolar range. Martyanov et al [29] have carried out a
comparison of Km and Vmax values for various primers in
the polymerization reaction catalyzed by the HIV-1 RT. The
aﬃnity of RT for complementary d(pT)6 containing two dif-
ferent 5 -end pyranone derivatives was two to three orders
of magnitude higher (Km = 3–15nM) than that of d(pT)6
(Km = 12.6mM). ODNs noncomplementary to poly(A)
template were not elongated by RT. However, derivatives
of d(CAGGTG) containing the 5 -terminal chromone and
coumarin related groups were eﬃcient primers showing Km
(30–300nM)andVmax(75%–93%)valuescomparablewith
that for d(pT)10 (800nM; 100%). The [d(CAGGTG)]ddT
ODN derivatives were eﬀective inhibitors of RT. The primer
function of derivatives of noncomplementary ODNs appears
to be due to the additional interactions of their 5 -terminal
groups with the enzyme tRNA-binding site.
Toddacoumaquinone is a coumarin-naphthoquinone
dimer, and it was synthesized through Diels-Alder reaction
between 8-(1-acetoxy-3-methyl-1, 3-butadienyl)-5, 7-dime-
thoxycoumarinand2-methoxy-1,4-benzoquinone[30].The
activitiesofToddacoumaquinoneagainstseveralviruseswere
examined. A weak activity (EC50 = 10μgr/mL) was observed
against Herpes simplex virus type 1 and 2 (HSV-1 and HSV-
2), but no activity was seen against HIV-1.
HO O O
Scheme 10: Umbelliferone.
Anewseriesof3,5-bis(arylidene)-4-piperidones, aschal-
cone analogues carrying variety of aryl and heteroaryl
groups, pyrazolo[4,3-c]pyridines, pyridolo[4,3-c]pyrimi-
dines, and pyrido[4,3-c]pyridines, carrying an arylidene
moiety,andaseriesofpyrano[3,2-c]pyridines,asﬂavoneand
coumarin isosteres, were synthesized [31] and screened for
their in vitro antiviral and antitumor activities at the Na-
tional Cancer Institute. Several compounds proved to be
active against HSV-1, while other compounds showed mod-
erate activity against HIV-1. The pyrano[3,2-c]pyridines
heterocyclic system proved to be the most active antitumors
among the investigated heterocycles.
A single dose of coumarin derivatives, warfarin (Scheme
8), 4-hydroxycoumarin (Scheme 9), and umbelliferone
(Scheme 10), added at the time of inoculation either by
free virus or by contact with U1 monocytes exhibited a
dose-dependent inhibitory eﬀect on viral replication in tar-
get MOLT-4 lymphocytes observable even at 5 days after
infection [32]. In addition, marked decrease of HIV-1 p24
release and reduction in RT activity was observed when
chronically HIV-infected ACH-2 lymphocytes were treated
with coumarins (ED50 range 10−6–10−9 mol/L). However,
theintracellularcompositionofHIV-1coreproteinsindrug-
exposedcellswasnotmodiﬁed.Resultssuggestthatalthough
nocompleteinhibitionofviralproductionhasbeenobserved
in vitro, this class of drugs may present potential interest as
antiviral agents.
Integraseinhibitors
The structures of a large number of HIV-1 integrase in-
hibitors have in common two aryl units separated by a
central linker. Frequently, at least one of these aryl moi-
eties must contain 1,2-dihydroxy substituents in order to ex-
hibit high inhibitory potency. The ability of o-dihydroxy-
containing species to undergo in situ oxidation to reactive
quinones presents a potential limitation to the utility of such
compounds. The report of tetrameric 4-hydroxycoumarin-
derived inhibitor provided a lead example of an inhibitor
which does not contain the catechol moiety. Tetrameric 4-
hydroxycoumarin-derivedinhibitorrepresentsalarge,highly
complex, yet symmetrical molecule. It was the purpose of
the study [33] to determine the critical components of
tetrameric 4-hydroxycoumarin-derived inhibitor, and if pos-
sible to simplify its structure while maintaining potency.
In the study, dissection of tetrameric 4-hydroxycoumarin-
derived inhibitor (IC50 = 1.5μM) into its constituent parts
showed that the minimum active pharmacophore consistedI. Kostova et al 7
of a coumarin dimer containing an aryl substituent on the
central linker methylene. However, in the simplest case in
which the central linker aryl unit consisted of a phenyl ring
(IC50 = 43μM), a signiﬁcant reduction in potency resulted
by removing two of the original four coumarin units. Re-
placement of this central phenyl ring by more extended aro-
matic systems having higher lipophilicity improved potency,
asdidtheadditionof7-hydroxysubstituentstothecoumarin
rings. Combining these latter two modiﬁcations resulted in
compounds such as 3,3 -(2-naphthalenomethylene)bis[4,7-
dihydroxycoumarin](IC50 = 4.2μM)whichexhibitednearly
the full potency of the parent tetramer, yet were structurally
much simpler.
The most important method that can be applied to de-
velop new anti-AIDS compounds is computer-assisted drug
design (CADD). The used method involves traditional or
classic QSAR and 3D QSAR. In the traditional approach to
QSAR, the chemical structure can be described with exper-
imental and theoretical steric, electronic, and hydrophobic
parameters. 3D QSAR methods were developed as an alter-
native to traditional QSAR to describe molecules. The results
indicatedthattheﬂavonoidswithhydroxylgroupsatC-5and
C-7 in the A-ring, and with a C-2-C-3 double bond were the
most potent HIV growth inhibitors [33]. According to the
above information on structure-activity relationships, struc-
ture modiﬁcation methods can be also used for ﬂavonoid
lead compounds, which are derived from plants with pos-
sible anti-HIV activity. As a potential target, the heteroatom
in position 1 of the C-ring of the ﬂavonoid compounds has
been considered. Therefore, similar or even new biological
activities could be anticipated when the oxygen of bioac-
tive ﬂavonoids is replaced by another atom such as nitro-
gen or sulfur, which lines up closely with oxygen in the peri-
odic table. Thus, a series of 5,6,7,8-subsituted-2-phenylthio-
chromen-4-oneshasbeensynthesizedandevaluatedforanti-
HIV activity [34]. Among them, one new compound was the
most active (IC50 value of 0.65μM) against HIV in acutely
infected H9 lymphocytes, and had a TI of approximately 5.
A systematic series of chemically modiﬁed coumarin dimers
has been synthesized and tested for their inhibitory activity
against HIV-1 integrase. Mao et al [35] observed that modi-
ﬁed coumarin dimers containing hydrophobic moiety on the
linker display potent inhibitory activities.
Proteaseinhibitors
HIV-1 protease has been identiﬁed as a signiﬁcant target
enzyme in AIDS research. While numerous peptide-derived
inhibitors have been described, the identiﬁcation of a
nonpeptide inhibitor remains an important goal. Using an
HIV-1 protease mass screening technique, 4-hydroxy-3-
(3-phenoxypropyl)-2H-1-benzopyran-2-one was identiﬁed
as a nonpeptide competitive inhibitor of the enzyme [36].
Employing a Monte Carlo-based docking procedure, the
coumarin was docked in the active site of the enzyme,
revealing a binding mode that was later conﬁrmed by the
X-ray crystal analysis. Several analogues were prepared
to test the binding interactions and improve the overall
O
HO
OH
O H3C
O
Scheme 11: 4,7-dihydroxy-3-[4-(2-methoxyphenyl)butyl]-2H-
chromen-2-one.
binding aﬃnity. The most active compound in the study was
4,7-dihydroxy-3-[4-(2-methoxyphenyl)butyl]-2H-1-benzo-
pyran-2-one (Scheme 11).
The screening of the HIV-1 protease (PR) inhibitory
activity (IC50) of various substituted 3-phenyl-4-hydroxy-
coumarins, 3-benzyl-4-hydroxycoumarins, 3-phenoxy-4-hy-
droxy-coumarins, 3-benzenesulfonyl-4-hydroxycoumarins,
and 3-(7-coumarinyloxy)-4-hydroxycoumarins was per-
formed [37]. The data indicate the importance of sub-
stituents at positions 5 and 7 of the coumarin ring on the
inhibitory potency of the HIV-1-PR.
The interaction of novel series of synthetic inhibitors
with various serine proteases (leukocyte elastase, throm-
bin, cathepsin G, chymotrypsin, plasminogen activators, and
plasmin) and an aspartic protease (HIV-1 protease) were
studied [38]. Various aspects were analyzed: mechanism of
action, structure-activity relationships, and in some cases,
molecular modeling, and biological evaluation. Function-
alized cyclopeptides and N-aryl azetidin-2-ones behaved as
suicide substrates acting speciﬁcally on trypsin-like pro-
teases (thrombin or urokinase) and elastases, respectively.
Novel hydrazinopeptides acted as reversible inhibitors of
elastases. Coumarin derivatives inactivated very eﬃciently
chymotrypsin-like proteases (k(inact)/K(I) = 760,000M
−1 ·
s−1). Inhibitors of HIV-1 protease acting either as inactiva-
tors or dimerization inhibitors are under investigation. The
inhibitors described above are useful for elucidating the bi-
ological roles of the target enzymes and constitute potential
drugs.
CONCLUSION
Coumarins comprise a vast array of biologically active com-
pounds ubiquitous in plants, many of which have been
used in traditional medicine for thousands of years. Of the
many actions of coumarins, antioxidant, antiproliferative,
and anti-HIV eﬀects stand out. A large number of struc-
turally novel coumarin derivatives have ultimately been re-
ported to show substantial anti-HIV activity. Given that
certain substituents are known to be required or increase
their actions, the therapeutic potential of select coumarins is
fairlyobvious.Thereisconsiderableevidencethatcoumarins
are important lead compounds for the development of
antiviral and/or virucidal drugs against HIV. To describe
the recent progress of the discovery, structure modiﬁcation
and structure-activity relationship of the potent anti-HIV
coumarin derivatives is not an easy task. Nevertheless, it is
useful to make some correlations of the available data which8 Bioinorganic Chemistry and Applications
would help the researchers in discovering and developing of
newactivecompoundsusedindrugdesign.Thescientiﬁcso-
ciety can modify the structures of many synthetic coumarin
derivatives, which are lead compounds for anti-HIV agents,
inordertodesignnewanti-AIDSdrugs.Themolecularmod-
eling methods may be a potential tool in the development of
new anti-HIV agents. Molecular modeling systems provide
powerful tools for building, visualizing, analyzing, and stor-
ingmodelsofcomplexmolecularsystems(ie,inhibitorbind-
ing with receptor) that can help interpret structure-activity
relationships.
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